ADAR2 restores bone cancer cells to a less aggressive state

By AI, Created 3:15 PM UTC, May 20, 2026, /AGP/ – Researchers in Italy found that reviving the RNA-editing enzyme ADAR2 pushed osteosarcoma cells toward bone-like differentiation in lab and mouse studies. The work suggests a new preclinical strategy for pediatric bone cancer by weakening tumor growth, invasion and drug resistance.

Why it matters: - Osteosarcoma is the most common primary bone cancer in children, adolescents and young adults. - The disease often returns or spreads to the lungs, where outcomes remain poor. - The study points to a differentiation-based strategy that could complement chemotherapy instead of relying only on cell-killing drugs.

What happened: - Researchers led by Dr. Andrea Del Fattore and Prof. Angela Gallo at Bambino Gesù Children’s Hospital in Rome tested whether restoring ADAR2 could reverse aggressive osteosarcoma behavior. - The findings were published in Bone Research on April 3, 2026. - The team used patient datasets, cell models, transcriptomic analysis and mouse studies. - The study found that ADAR2 levels rise as healthy mesenchymal stem cells mature into osteoblasts. - Osteosarcoma tissues and highly aggressive cell lines showed lower ADAR2 expression. - Lower ADAR2 levels tracked with poorer metastasis-free survival and overall survival in patient datasets.

The details: - Increasing ADAR2 in osteosarcoma cells slowed growth, reduced invasion and cut migration. - In one model, treated cells produced mineralized matrix, a sign of mature bone tissue. - Genes linked to osteoblast differentiation increased. - Markers tied to stemness and malignancy declined. - In mice implanted with human osteosarcoma cells, ADAR2-restored tumors were smaller and less invasive. - The treated tumors were less likely to spread to the lungs or liver. - Some mice developed minimal tumor burden compared with controls. - ADAR2-restored cells became more sensitive to methotrexate and selected anti-cancer compounds. - The team identified IGFBP7 as one of the strongest RNA-editing targets of ADAR2. - Edited IGFBP7 no longer promoted growth-related IGF signaling as strongly. - The edited form instead supported bone-development regulators such as runt-related transcription factor 2. - The original paper is titled “ADAR2 induces the differentiation of osteosarcoma cells by editing activity on IGFBP7: new implications for therapy.” - The paper DOI is 10.1038/s41413-026-00516-6. - The study was supported by Italian ministry and AIRC grants, EU NextGenerationEU funding and Fondazione Veronesi Post-Doctoral Fellowships.

Between the lines: - The results suggest osteosarcoma cells may be pushed out of an immature, aggressive state rather than only destroyed. - That matters because differentiation therapy can make cancer cells less able to grow, invade and resist treatment. - The work also adds to growing evidence that RNA editing can shape tumor behavior in multiple cancers. - Prof. Gallo said the findings open the way to new therapeutic targets for osteosarcoma and other tumors.

What’s next: - The findings are preclinical, so the next step is testing whether ADAR2-based approaches can be translated into human therapy. - Future work will likely focus on how to safely restore ADAR2 activity in patients. - The study could also spur collaboration among pediatric oncologists, RNA biologists and drug developers. - Researchers expect the broader idea of cancer-cell reprogramming toward maturation to be explored in additional tumors.

The bottom line: - Restoring ADAR2 turned aggressive osteosarcoma cells toward a more mature bone-like state and made them less dangerous in early models.